Differences
This shows you the differences between two versions of the page.
| Next revision | Previous revision | ||
|
biochem_4c03_2022_winter [2021/12/03 16:05] yang created |
biochem_4c03_2022_winter [2022/01/19 16:15] (current) yang |
||
|---|---|---|---|
| Line 1: | Line 1: | ||
| - | [[Example Page]] | + | [[Example Page]]; |
| - | [[Group_1_TA_Agata_Kieliszek_Presentation_1 ]]; | + | [[Group_1_TA_Agata_Kieliszek_Immune_responses_against_SARS-CoV-2_Presentation_1]]; |
| - | [[Group_2_TA_Nathan_Roberge_Presentation_1 ]]; | + | [[Group_2_TA_Nathan_Roberge_Pathogenesis_and_transmission_of_SARS-CoV-2_Presentation_1]]; |
| - | [[Group_3_TA_Agata_Kieliszek_Presentation_1 ]]; | + | [[Group_3_TA_Agata_Kieliszek_Therapeutic_targeting_of_SARS-CoV-2_Presentation_1]]; |
| - | [[Group_4_TA_Nathan_Roberge_Presentation_1 ]]; | + | [[Group_4_TA_Nathan_Roberge_Vaccine_treatment_of_SARS-CoV-2_Presentation_1]]; |
| - | [[Group_5_TA_Agata_Kieliszek_Presentation_1 ]]; | + | [[Group_5_TA_Agata_Kieliszek_Stem_cell_models_and/or_therapies_for_SARS-CoV-2_Presentation_1]]; |
| + | |||
| + | [[Group_6_TA_Nathan_Roberge_Diagnostics_of_SARS-CoV-2_Presentation_1]]; | ||
| + | |||
| + | [[Group_1_TA_Agata_Kieliszek_Immune_responses_against_SARS-CoV-2_Presentation_2]]; | ||
| + | |||
| + | [[Group_2_TA_Nathan_Roberge_Pathogenesis_and_transmission_of_SARS-CoV-2_Presentation_2]]; | ||
| + | |||
| + | [[Group_3_TA_Agata_Kieliszek_Therapeutic_targeting_of_SARS-CoV-2_Presentation_2]]; | ||
| + | |||
| + | [[Group_4_TA_Nathan_Roberge_Vaccine_treatment_of_SARS-CoV-2_Presentation_2]]; | ||
| + | |||
| + | [[Group_5_TA_Agata_Kieliszek_Stem_cell_models_and/or_therapies_for_SARS-CoV-2_Presentation_2]]; | ||
| + | |||
| + | [[Group_6_TA_Nathan_Roberge_Diagnostics_of_SARS-CoV-2_Presentation_2]]; | ||
| + | |||
| + | |||
| + | |||
| + | {{:4c03_2022_class_list_v4.png?200|}} | ||
| - | [[Group_6_TA_Nathan_Roberge_Presentation_1 ]]; | ||
